We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Buying Brown and Brown (BRO) Stock Seems Prudent
Read MoreHide Full Article
Brown and Brown’s (BRO - Free Report) solid segmental performance, sturdy financial position and effective capital deployment along with favorable growth estimates make it a good investment choice.
This insurance broker has a solid track of beating earnings estimates in the last eight years. Its net earnings per share witnessed a five-year CAGR of 14%.
Zacks Rank & Price Performance
Brown and Brown currently carries a Zacks Rank #2 (Buy). In a year’s time, the stock has rallied 49.9%, outperforming the industry’s increase of 21.4%, the Finance sector’s rise of 21.2% and the S&P 500’s rally of 25.3%.
Image Source: Zacks Investment Research
Growth Projections
The Zacks Consensus Estimate for 2022 earnings is pegged at 2.27, up 5.1% on about 8% higher revenues of $3.3 billion.
Estimate Revision
The Zacks Consensus Estimate for 2022 earnings has moved north by a cent in the past seven days, reflecting analyst optimism.
Business Tailwinds
Increasing commissions and fees across its segments continue to drive the top line for Brown and Brown. Revenues witnessed a 10-year CAGR of 10% and exceeded the peer average and the S&P 500. Improving new business, solid retention and continued rate increases for most lines of coverage should help retain the growth momentum.
Brown & Brown has an impressive inorganic story, acquiring more than 500 insurance intermediary operations in more than two decades. Strategic acquisitions helped it strengthen its compelling products and service portfolio while expanding its global reach.
Strategic investments to drive organic growth, improve efficiency and margin bode well for BRO.
Strong Capital Position
Brown and Brown maintains a solid balance sheet with sufficient liquidity and low leverage. Banking on its stable cash flow, BRO has raised dividends for the last 28 years at a five-year CAGR of 8.7% besides engaging in share buybacks. Free cash flow witnessed a 10-year CAGR of 9%.
Brown and Brown boasts a five-year total shareholder return of 205%, much above its peer group and the S&P 500.
The Zacks Consensus Estimate for Marsh & McLennan’s 2022 earnings stands at $6.74, indicating an increase of 9.5% year over year. The consensus estimate has moved up by a cent in the past seven days. The expected long-term earnings growth is 12.9%, better than the industry average of 12.6%.
The Zacks Consensus Estimate for Ryan Specialty’s 2022 earnings stands at $1.22, implying an increase of 13.6% year over year. The consensus estimate has moved up by a cent in the past seven days. Ryan Specialty delivered an earnings surprise of 41.18% in the last reported quarter.
The Zacks Consensus Estimate for Willis Towers Watson’s 2022 earnings stands at $13.88, suggesting a 5.9% year-over-year increase. Willis Towers Watson delivered a four-quarter average earnings surprise of 15.27%.
Shares of Marsh & McLennan, Ryan Specialty and Willis Towers Watson have gained 46.4%, 33.6% and 12.5% in a year’s time.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Buying Brown and Brown (BRO) Stock Seems Prudent
Brown and Brown’s (BRO - Free Report) solid segmental performance, sturdy financial position and effective capital deployment along with favorable growth estimates make it a good investment choice.
This insurance broker has a solid track of beating earnings estimates in the last eight years. Its net earnings per share witnessed a five-year CAGR of 14%.
Zacks Rank & Price Performance
Brown and Brown currently carries a Zacks Rank #2 (Buy). In a year’s time, the stock has rallied 49.9%, outperforming the industry’s increase of 21.4%, the Finance sector’s rise of 21.2% and the S&P 500’s rally of 25.3%.
Growth Projections
The Zacks Consensus Estimate for 2022 earnings is pegged at 2.27, up 5.1% on about 8% higher revenues of $3.3 billion.
Estimate Revision
The Zacks Consensus Estimate for 2022 earnings has moved north by a cent in the past seven days, reflecting analyst optimism.
Business Tailwinds
Increasing commissions and fees across its segments continue to drive the top line for Brown and Brown. Revenues witnessed a 10-year CAGR of 10% and exceeded the peer average and the S&P 500. Improving new business, solid retention and continued rate increases for most lines of coverage should help retain the growth momentum.
Brown & Brown has an impressive inorganic story, acquiring more than 500 insurance intermediary operations in more than two decades. Strategic acquisitions helped it strengthen its compelling products and service portfolio while expanding its global reach.
Strategic investments to drive organic growth, improve efficiency and margin bode well for BRO.
Strong Capital Position
Brown and Brown maintains a solid balance sheet with sufficient liquidity and low leverage. Banking on its stable cash flow, BRO has raised dividends for the last 28 years at a five-year CAGR of 8.7% besides engaging in share buybacks. Free cash flow witnessed a 10-year CAGR of 9%.
Brown and Brown boasts a five-year total shareholder return of 205%, much above its peer group and the S&P 500.
Other Stocks to Consider
Investors interested in the same space can look at Marsh & McLennan Companies (MMC - Free Report) , Ryan Specialty Group (RYAN - Free Report) and Willis Towers Watson plc (WTW - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) here.
The Zacks Consensus Estimate for Marsh & McLennan’s 2022 earnings stands at $6.74, indicating an increase of 9.5% year over year. The consensus estimate has moved up by a cent in the past seven days. The expected long-term earnings growth is 12.9%, better than the industry average of 12.6%.
The Zacks Consensus Estimate for Ryan Specialty’s 2022 earnings stands at $1.22, implying an increase of 13.6% year over year. The consensus estimate has moved up by a cent in the past seven days. Ryan Specialty delivered an earnings surprise of 41.18% in the last reported quarter.
The Zacks Consensus Estimate for Willis Towers Watson’s 2022 earnings stands at $13.88, suggesting a 5.9% year-over-year increase. Willis Towers Watson delivered a four-quarter average earnings surprise of 15.27%.
Shares of Marsh & McLennan, Ryan Specialty and Willis Towers Watson have gained 46.4%, 33.6% and 12.5% in a year’s time.